Latest by Polly Clayden
VRC01 in HIV-Exposed Newborns: First Results Support Monthly Injections for Those at Risk Through Breastfeeding
Preliminary results suggest that VRC01 -- an investigational HIV neutralising monoclonal antibody -- administered subcutaneously to neonates is safe and well tolerated.
Daily raltegravir was safe and well tolerated at six weeks of life and met pharmacokinetic targets in HIV-exposed infants, according to data presented at CROI 2017.
Tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) exposures are slightly higher in children aged 6-12 years compared with adults.
The prevalence of transmitted drug resistance is above the WHO threshold of 5% in this study conducted in rural South Africa.
No increase in poor birth outcomes with PrEP used throughout pregnancy in the Partners Demonstration project.
First in-human trial results of nanoformulations of efavirenz and lopinavir confirmed the potential for a 50% dose reduction to the current standard oral dose of both antiretrovirals.
Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity
Serious toxicities were seen in participants in a drug-drug interaction study of once-weekly isoniazid and rifapentine with once-daily dolutegravir, leading to its early termination.
Two cohort studies presented at CROI 2017 showed a higher risk of IRIS with integrase inhibitor-based ART than with other regimens.
Launched at CROI 2017, this new edition of an annual i-Base publication reviews and updates current and planned research for treatment optimzation studies.
A new analysis reports that HIV-positive women in clinical trials in sub-Saharan Africa are likely to get pregnant as often as those receiving care outside of research settings.